Literature DB >> 20607826

Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor.

Katrin Singer1, Michael Kastenberger, Eva Gottfried, Christine G Hammerschmied, Maike Büttner, Michael Aigner, Barbara Seliger, Bernhard Walter, Hans Schlösser, Arndt Hartmann, Reinhard Andreesen, Andreas Mackensen, Marina Kreutz.   

Abstract

Many tumor cells are characterized by a dysregulated glucose metabolism associated with increased glycolysis in the presence of oxygen ("Warburg Effect"). Here, we analyzed for the first time a possible link between glucose metabolism and immune cell infiltration in renal cell carcinoma (RCC). RCC specimens revealed a highly significant increase in the expression of lactate dehydrogenase A (LDHA) and glucose-transporter 1 (GLUT-1) compared to the corresponding normal kidney tissue on mRNA level. Accordingly, tumor cell lines of different origin such as RCC, melanoma and hepatocellular carcinoma strongly expressed LDHA and GLUT-1 compared to their nonmalignant counterparts. In line with this finding, tumor cells secreted high amounts of lactate. High expression of GLUT-1 and LDH5, a tetramer of 4 LDHA subunits, was confirmed by tissue microarray analysis of 249 RCC specimens. Overall, 55/79 (69.6%) and 46/71 (64.7%) cases of clear cell carcinoma showed a constitutive, but heterogeneous expression of GLUT-1 and LDH5, respectively. The number of CD3(+), CD8(+) and FOXP3(+) T cells was significantly elevated in RCC lesions compared to normal kidney epithelium, but effector molecules such as granzyme B and perforin were decreased in tumor infiltrating T cells. Of interest, further analysis revealed an inverse correlation between GLUT-1 expression and the number of CD8(+) T cells in RCC lesions. Together, our data suggest that an accelerated glucose metabolism in RCC tissue is associated with a low infiltration of CD8(+) effector T cells. Targeting the glucose metabolism may represent an interesting tool to improve the efficacy of specific immunotherapeutic approaches in RCC.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20607826     DOI: 10.1002/ijc.25543

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  55 in total

1.  Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.

Authors:  Tina Cascone; Jodi A McKenzie; Rina M Mbofung; Simone Punt; Zhe Wang; Chunyu Xu; Leila J Williams; Zhiqiang Wang; Christopher A Bristow; Alessandro Carugo; Michael D Peoples; Lerong Li; Tatiana Karpinets; Lu Huang; Shruti Malu; Caitlin Creasy; Sara E Leahey; Jiong Chen; Yuan Chen; Helen Pelicano; Chantale Bernatchez; Y N Vashisht Gopal; Timothy P Heffernan; Jianhua Hu; Jing Wang; Rodabe N Amaria; Levi A Garraway; Peng Huang; Peiying Yang; Ignacio I Wistuba; Scott E Woodman; Jason Roszik; R Eric Davis; Michael A Davies; John V Heymach; Patrick Hwu; Weiyi Peng
Journal:  Cell Metab       Date:  2018-04-05       Impact factor: 27.287

2.  Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.

Authors:  Rosemarie Krupar; Katharina Robold; Doris Gaag; Gerrit Spanier; Marina Kreutz; Kathrin Renner; Claus Hellerbrand; Ferdinand Hofstaedter; Anja K Bosserhoff
Journal:  Virchows Arch       Date:  2014-07-16       Impact factor: 4.064

Review 3.  Metabolic reprogramming in clear cell renal cell carcinoma.

Authors:  Hiromi I Wettersten; Omran Abu Aboud; Primo N Lara; Robert H Weiss
Journal:  Nat Rev Nephrol       Date:  2017-05-08       Impact factor: 28.314

4.  Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1.

Authors:  Jing-Jing Wang; Michelle K Siu; Yu-Xin Jiang; Thomas H Leung; David W Chan; Ran-Ran Cheng; Annie N Cheung; Hextan Y Ngan; Karen K Chan
Journal:  Oncoimmunology       Date:  2019-09-05       Impact factor: 8.110

5.  The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry.

Authors:  Carole Fakhry; Klaus K Andersen; Jane Christensen; Nishant Agrawal; David W Eisele
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-20

Review 6.  Metabolic requirements of the nephron.

Authors:  Kasey Cargill; Sunder Sims-Lucas
Journal:  Pediatr Nephrol       Date:  2018-12-15       Impact factor: 3.714

Review 7.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 8.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Authors:  Kristin G Anderson; Ingunn M Stromnes; Philip D Greenberg
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

Review 9.  PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.

Authors:  Lauren C Harshman; Charles G Drake; Toni K Choueiri
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

10.  Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Authors:  Frederik C Henrich; Katrin Singer; Kerstin Poller; Luise Bernhardt; Carolin D Strobl; Katharina Limm; Axel P Ritter; Eva Gottfried; Simon Völkl; Benedikt Jacobs; Katrin Peter; Dimitrios Mougiakakos; Katja Dettmer; Peter J Oefner; Anja-Katrin Bosserhoff; Marina P Kreutz; Michael Aigner; Andreas Mackensen
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.